Having a migraine is hard. It can be even harder to watch your child experience a painful and debilitating migraine attack without the ability to help.
We are inviting your child to take part in a clinical study for children of 6 to 17 years of age who suffer from migraine headaches. All study-related visits, tests, and investigational product will be provided at no cost. In addition, you may receive compensation for your time and travel. No health insurance is required to participate.
The KALEIDOSCOPE Study is evaluating an investigational product for the prevention of migraine headaches in children between the ages of 6 to 17. The investigational product is currently approved to prevent migraine in adults. The safety and effectiveness of this investigational product in children is unknown.
Your child may qualify for the KALEIDOSCOPE Study if they:
- Are between the ages of 6-17 years old
- Have been diagnosed with migraine headaches for at least 6 months
- Experience between 4 and 14 migraine headache days per month
After completing the KALEIDOSCOPE study, you may be eligible to participate in a voluntary open-label extension study at no cost, for up to two years.
Sign Up
What happens if I sign up? We will match your child to a study site location in your area that are accepting participants between the ages of 6-17 who experience migraine or notify you when one becomes available. The study team will then contact you and you may have the opportunity to participate if your child qualifies.
If you think your child might like to participate in the KALEIDOSCOPE Study or would like more information, please enter your child’s information below so we can see if your child may qualify and can contact you about the studies. Keep in mind that participation is entirely voluntary. If you and your child decide to take part in a study, you and your child may change your mind about participating at any time.
If you are reading this and fit the age criteria for the study, let your parent or guardian know so they can review and complete the online screener below with you.
About Pediatric Migraine
Migraine is a severe, chronic neurological disease characterized by episodic attacks of moderate-to-severe headache, sensory disturbances, and other symptoms. Migraine represents a major cause of disability in adults and in children.
Although the peak prevalence of the condition typically occurs during adulthood, migraine disease represents one of the most common childhood ailments.1
The prevalence of migraine in children is estimated at 7% to 10%, and about one-third of people with migraine experience their first attack before adulthood.2 Among children, a headache is the most common symptom and the most common source of pain when experiencing a migraine attack.3
An accurate and timely diagnosis of migraine disease is vital to ensure prompt treatment of the disease. To diagnose migraine headaches in children, the same criteria are used to diagnose adults, but with differences in duration.4
The KALEIDOSCOPE Study is evaluating an investigational product for the prevention of migraine headaches in children between the ages of 6 to 17. The investigational product is currently approved to treat migraine in adults. The safety and effectiveness of this investigational product in children is unknown.
Frequently Asked Questions
What is a clinical trial?
A clinical trial is a medical study that helps to answer important questions about an investigational drug – these may include whether an investigational study drug works for a certain condition. All medications must be tested in clinical research studies before they can be approved and prescribed to patients.
Why are clinical trials important?
A clinical study is the basis on which investigational products are evaluated to determine if they can be approved and brought to market.
What is the purpose of the KALEIDOSCOPE Study?
The KALEIDOSCOPE Study is evaluating an investigational product for the prevention of migraine headaches in children between the ages of 6 to 17.
The investigational product is currently approved to prevent migraine in adults. The safety and effectiveness of this investigational product in children is unknown.
What will the KALEIDOSCOPE Study involve?
The KALEIDOSCOPE Study will last as short as several weeks or for up to 4 months. Over 450 children and adolescents will be enrolled in the study, which is being conducted at study sites across the world, including United States and Puerto Rico.
Eligible participants will receive the investigational product or the placebo. The study team will provide more information when they contact you.
After completing the KALEIDOSCOPE study, you may be eligible to participate in a voluntary open-label extension study at no cost, for up to two years.
Will I receive compensation?
Volunteers who qualify to take part in the study may receive compensation for time and travel. Please discuss this with the study team at the site when they contact you.
Is there a cost to participate?
There is no cost to participate in the KALEIDOSCOPE Study. If your child decides to take part:
- Your child will receive study-related care throughout the study from a team of experienced doctors and nurses
- All study-related visits, tests, and investigational product will be provided at no cost
What else do I need to consider?
The research team will be able to explain more about what the KALEIDOSCOPE Study will involve, and it is up to you and your child to decide if your child wants to take part. Participation in this study is voluntary. Whether or not you and your child decide to participate in this study will not affect your current or future relationships with your doctors. If you and your child decide to participate, your child is free to withdraw at any time without affecting those relationships.
How far is the study site?
We match your child to a study site within a close travel distance from your home. If we are not running the study in your area currently, with your permission, we will keep you in our database and reach out once a study in your area becomes available. If, at any time, you decided you no longer want your information stored, you can opt out and we will delete your details.
About the KALEIDOSCOPE Study
The KALEIDOSCOPE Study will enroll over 450 children between the ages of 6 to 17 years old who suffer from migraine across the world, including United States and Puerto Rico.
The study will include about 7 visits to a study site in your location. Your child’s participation may be as short as several weeks or for up to 4 months. After completing the KALEIDOSCOPE study, you may be eligible to participate in a voluntary open-label extension study at no cost, for up to two years.
Your child may qualify for the KALEIDOSCOPE Study if they:
- Are between the ages of 6-17 years old
- Have been diagnosed with migraine headaches for at least 6 months
- Experience between 4 and 14 migraine headache days per month
All study-related visits, tests, and investigational product will be provided at no cost to you or your insurance. In addition, compensation for time and travel may be provided.
